Loading
Phanes Therapeutics is a San Diego biotech whose bispecific antibodies pair a tumour antigen with an immune signal; peluntamig hits DLL3 and CD47 in small cell lung cancer and spevatamig hits Claudin 18.2 and CD47 in stomach and pancreatic cancer.
Phanes Therapeutics develops bispecific antibodies using its PACbody, SPECpair and ATACCbody platforms. Peluntamig (PT217) binds DLL3 and CD47 and has orphan and fast track designations in small cell lung cancer and neuroendocrine carcinomas; spevatamig (PT886) binds Claudin 18.2 and CD47 for gastric and pancreatic cancers; mavrostobart (PT199) is a CD73 antibody being tested with PD-1 blockade and chemotherapy. All three are in phase 1/2 trials.
Peluntamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and neuroendocrine tumours, aimed at CD47 and DLL3.
Spevatamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, aimed at Claudin 18.2 and CD47.
Mavrostobart is an experimental monoclonal antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at CD73 / adenosine axis.
Shares Spevatamig, Peluntamig.
Shares Spevatamig, Peluntamig, A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study), Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct.
Shares Mavrostobart, Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy.
Shares Peluntamig, A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/